Potential Parkinson’s Disease Treatment Yields Promising Study Results

Stimvia’s completed pilot study focused on Parkinson’s disease (PD) reportedly is showing encouraging results.

Twelve Parkinson’s Disease patients participated in the study. For six weeks, the patients used Stimvia’s URIS device for 30-minute daily stimulation sessions; this phase was followed by another six-week period without stimulation, during which they continued to be monitored to assess whether the retained any positive effects from the earlier treatment. Participants reported improvements in their symptoms and overall quality of life, as well as fewer resting tremors, according to investigators.

“We are pleased to share preliminary findings indicating promising results. Patients have reported improvements in both the number of Parkinson’s disease symptoms and their overall quality of life. Furthermore, we have observed a notable reduction in resting tremor,” stated Prof. David Skoloudik, M.D., Ph.D., the study’s lead and vice dean for Science and Research at the Medical Faculty of Ostrava University. “While the precise data are still under rigorous evaluation, we remain cautiously optimistic about the potential implications of these outcomes.” 

The pilot study results give the company hope it can soon begin treating PD patients with its URIS technology. In the United States, an estimated 1 million people are affected by Parkinson’s disease conditions, with 10 million affected globally. Parkinson’s disease ranks as the second most prevalent neurodegenerative disorder after Alzheimer’s disease.

“Since the URIS technology demonstrated a positive impact in treating Parkinson’s Disease, Stimvia plans substantial investment in further clinical trials to validate the method’s efficacy and safety. We believe our technology can introduce new, additive treatment modalities for millions of patients who currently have no other options, potentially offering a positive disease-modifying impact on those with Parkinson’s disease,” Stimvia CEO Lukas Doskocil commented.

Complete study data will be revealed in the upcoming months.

Stimvia is a clinical-stage medtech company focused on developing and commercializing non-invasive therapies for chronic diseases.  With years of research and a series of clinical studies, Stimvia has developed a unique technology known as URIS, featuring the peroneal neuromodulation method (eTNM). This approach marks the first-ever non-invasive technique for stimulating deep brain structures, where many chronic diseases originate. Current clinical studies reveal that Stimvia’s technology is among the most effective in treating conditions like an overactive bladder, which impacts approximately 40 million individuals in the United States. The company’s key technological components and methods are safeguarded by more than 100 international patents across the European Union, Japan, Russia, and the United States.